The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
New Oral Anticoagulants in Atrial Fibrillation and Acute Coronary Syndromes
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dabigatran versus warfarin in patients with atrial fibrillation
Connolly, S. J., Ezekowitz, M. D., Yusuf, S., Eikelboom, J., Oldgren, J., Parekh, A., Pogue, J., Reilly, P. A., Themeles, E., Varrone, J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0905561 · Cited by 11,215
Rivaroxaban versus warfarin in nonvalvular atrial fibrillation
Patel, M. R., Mahaffey, K. W., Garg, J., Pan, G., Singer, D. E., Hacke, W., Breithardt, G., Halperin, J. L., Hankey, G. J., Piccini, J. P., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1009638 · Cited by 9,430
Apixaban versus warfarin in patients with atrial fibrillation
Granger, C. B., Alexander, J. H., McMurray, J. J. V., Lopes, R. D., Hylek, E. M., Hanna, M., Al-Khalidi, H. R., Ansell, J., Atar, D., Avezum, A., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1107039 · Cited by 8,943
Roffi, M., Patrono, C., Collet, J.-P., Mueller, C., Valgimigli, M., Andreotti, F., Bax, J. J., Borger, M. A., Brotons, C., Chew, D. P., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehv320 · Cited by 8,261
Self-citationWriting Committee Members, Levine, G. N., Bates, E. R., Blankenship, J. C., Bailey, S. R., Bittl, J. A., Cercek, B., Chambers, C. E., Ellis, S. G., Guyton, R. A., et al. (2011) · Circulation · doi:10.1161/cir.0b013e31823ba622 · Cited by 3,289
Authors/Task Force Members, Hamm, C. W., Bassand, J.-P., Agewall, S., Bax, J., Boersma, E., Bueno, H., Caso, P., Dudek, D., Gielen, S., et al. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr236 · Cited by 3,080
Self-citationApixaban in patients with atrial fibrillation
Connolly, S. J., Eikelboom, J., Joyner, C., Diener, H.-C., Hart, R., Golitsyn, S., Flaker, G., Avezum, A., Hohnloser, S. H., Diaz, R., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1007432 · Cited by 2,483 · cited 1×
“The first published results on the efficacy of FXa inhibitors for stroke prevention in atrial fibrillation come from the AVERROES (Apixaban VERsus acetylsalicylic acid to pRevent strOkE in atrial fibrillation patientS who have failed or are unsuitable for vitamin K antagonist treatment) trial (19).”
Background2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention
Levine, G. N., Bates, E. R., Blankenship, J. C., Bailey, S. R., Bittl, J. A., Cercek, B., Chambers, C. E., Ellis, S. G., Guyton, R. A., Hollenberg, S. M., et al. (2011) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2011.08.007 · Cited by 2,164
Rivaroxaban in Patients with a Recent Acute Coronary Syndrome
Mega, J. L., Braunwald, E., Wiviott, S. D., Bassand, J.-P., Bhatt, D. L., Bode, C., Burton, P., Cohen, M., Cook-Bruns, N., Fox, K. A. A., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1112277 · Cited by 1,897
Self-citationFox, K. A. A., Dabbous, O. H., Goldberg, R. J., Pieper, K. S., Eagle, K. A., Van de Werf, F., Avezum, Á., Goodman, S. G., Flather, M. D., Anderson, F. A., et al. (2006) · BMJ · doi:10.1136/bmj.38985.646481.55 · Cited by 1,693
Eerenberg, E. S., Kamphuisen, P. W., Sijpkens, M. K., Meijers, J. C., Buller, H. R., & Levi, M. (2011) · Circulation · doi:10.1161/circulationaha.111.029017 · Cited by 1,361
Wallentin, L., Yusuf, S., Ezekowitz, M. D., Alings, M., Flather, M., Franzosi, M. G., Pais, P., Dans, A., Eikelboom, J., Oldgren, J., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61194-4 · Cited by 1,013
Self-citationApixaban with Antiplatelet Therapy after Acute Coronary Syndrome
Alexander, J. H., Lopes, R. D., James, S., Kilaru, R., He, Y., Mohan, P., Bhatt, D. L., Goodman, S., Verheugt, F. W., Flather, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1105819 · Cited by 1,005
Self-citationDecline in Rates of Death and Heart Failure in Acute Coronary Syndromes, 1999-2006
Fox, K. A. A., Steg, P. G., Eagle, K. A., Goodman, S. G., Anderson, F. A., Granger, C. B., Flather, M. D., Budaj, A., Quill, A., Gore, J. M., et al. (2007) · JAMA · doi:10.1001/jama.297.17.1892 · Cited by 879
Warfarin, Aspirin, or Both after Myocardial Infarction
Hurlen, M., Abdelnoor, M., Smith, P., Erikssen, J., & Arnesen, H. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020496 · Cited by 846
Self-citationNewly identified events in the RE-LY trial
Connolly, S. J., Ezekowitz, M. D., Yusuf, S., Reilly, P. A., & Wallentin, L. (2010) · New England Journal of Medicine · doi:10.1056/nejmc1007378 · Cited by 688
Self-citationMega, J., Braunwald, E., Mohanavelu, S., Burton, P., Poulter, R., Misselwitz, F., Hricak, V, Barnathan, E., Bordes, P., Witkowski, A., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60738-8 · Cited by 688
Sørensen, R., Hansen, M. L., Abildstrom, S. Z., Hvelplund, A., Andersson, C., Jørgensen, C., Madsen, J. K., Hansen, P. R., Køber, L., Torp-Pedersen, C., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61751-7 · Cited by 575
Oldgren, J., Budaj, A., Granger, C. B., Khder, Y., Roberts, J., Siegbahn, A., Tijssen, J. G. P., Van de Werf, F., Wallentin, L., & for the RE-DEEM Investigators (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr113 · Cited by 534
Self-citationRuff, C. T., Giugliano, R. P., Antman, E. M., Crugnale, S. E., Bocanegra, T., Mercuri, M., Hanyok, J., Patel, I., Shi, M., Salazar, D., et al. (2010) · American Heart Journal · doi:10.1016/j.ahj.2010.06.042 · Cited by 480
APPRAISE Steering Committee and Investigators (2009) · Circulation · doi:10.1161/circulationaha.108.832139 · Cited by 461
Ezekowitz, M. D., Reilly, P. A., Nehmiz, G., Simmers, T. A., Nagarakanti, R., Parcham-Azad, K., Pedersen, K. E., Lionetti, D. A., Stangier, J., & Wallentin, L. (2007) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2007.06.034 · Cited by 419
Self-citationHohnloser, S. H., Oldgren, J., Yang, S., Wallentin, L., Ezekowitz, M., Reilly, P., Eikelboom, J., Brueckmann, M., Yusuf, S., & Connolly, S. J. (2012) · Circulation · doi:10.1161/circulationaha.111.055970 · Cited by 348
Self-citationConnolly, S., Patel, I., Salazar, D., Rohatagi, S., Mendell, J., Kastrissios, H., Jin, J., Kunitada, S., & Weitz, J. (2010) · Thrombosis and Haemostasis · doi:10.1160/th10-01-0066 · Cited by 341
Self-citationStangier, J., Eriksson, B. I., Dahl, O. E., Ahnfelt, L., Nehmiz, G., Stähle, H., Rathgen, K., & Svärd, R. (2005) · The Journal of Clinical Pharmacology · doi:10.1177/0091270005274550 · Cited by 296
Antiplatelet agents for the treatment and prevention of atherothrombosis
Patrono, C., Andreotti, F., Arnesen, H., Badimon, L., Baigent, C., Collet, J.-P., De Caterina, R., Gulba, D., Huber, K., Husted, S., et al. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr373 · Cited by 243
Self-citationDabigatran: An Oral Novel Potent Reversible Nonpeptide Inhibitor of Thrombin
Eisert, W. G., Hauel, N., Stangier, J., Wienen, W., Clemens, A., & van Ryn, J. (2010) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.110.203604 · Cited by 216
Steg, P. G., Mehta, S. R., Jukema, J. W., Lip, G. Y. H., Gibson, C. M., Kovar, F., Kala, P., Garcia-Hernandez, A., Renfurm, R. W., & Granger, C. B. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr334 · Cited by 186
Self-citationSimoons, M. L., Bobbink, I. W. G., Boland, J., Gardien, M., Klootwijk, P., Lensing, A. W. A., Rużyłło, W., Umans, V. A. W. M., Vahanian, A. S., de Werf, F. V., et al. (2004) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2004.02.051 · Cited by 141
Anticoagulants in heart disease: current status and perspectives
Caterina, R. D., Husted, S., Wallentin, L. C., Agnelli, G., Bachmann, F., Baigent, C., Jespersen, J., Kristensen, S., Montalescot, G., Siegbahn, A. G., et al. (2007) · European Heart Journal · doi:10.1093/eurheartj/ehl492 · Cited by 138
Self-citationGibson, C. M., Mega, J. L., Burton, P. B. J., Goto, S., Verheugt, F. W. A., Bode, C., Plotnikov, A. N., Sun, X., Cook‐Bruns, N., & Braunwald, E. (2011) · American Heart Journal · doi:10.1016/j.ahj.2011.01.026 · Cited by 96
Self-citationFactor Xa and thrombin as targets for new oral anticoagulants
Weitz, J. I. (2010) · Thrombosis Research · doi:10.1016/s0049-3848(10)70147-x · Cited by 80
Self-citationJiang, J., Hu, Y., Zhang, J., Yang, J., Mueck, W., Kubitza, D., Bauer, R., Meng, L., & Hu, P. (2009) · Thrombosis and Haemostasis · doi:10.1160/th09-03-0196 · Cited by 71
Secchiero, P., & Zauli, G. (2008) · Circulation · doi:10.1161/circulationaha.108.765776 · Cited by 5
Cited by
2012 focused update of the ESC Guidelines for the management of atrial fibrillation
Authors/Task Force Members, Camm, A. J., Lip, G. Y. H., De Caterina, R., Savelieva, I., Atar, D., Hohnloser, S. H., Hindricks, G., Kirchhof, P., ESC Committee for Practice Guidelines (CPG), et al. (2012) · EP Europace · doi:10.1093/europace/eus305 · Cited by 3,822
Self-citation2012 focused update of the ESC Guidelines for the management of atrial fibrillation
Authors/Task Force Members, Camm, A. J., Lip, G. Y. H., De Caterina, R., Savelieva, I., Atar, D., Hohnloser, S. H., Hindricks, G., Kirchhof, P., ESC Committee for Practice Guidelines (CPG), et al. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs253 · Cited by 2,899
Self-citation(2014) · European Heart Journal · doi:10.1093/eurheartj/ehu282 · Cited by 1,656
Heidbuchel, H., Verhamme, P., Alings, M., Antz, M., Diener, H.-C., Hacke, W., Oldgren, J., Sinnaeve, P., Camm, A. J., & Kirchhof, P. (2015) · Europace · doi:10.1093/europace/euv309 · Cited by 1,113
Heidbuchel, H., Verhamme, P., Alings, M., Antz, M., Hacke, W., Oldgren, J., Sinnaeve, P., Camm, A. J., & Kirchhof, P. (2013) · Europace · doi:10.1093/europace/eut083 · Cited by 792
Metadata
- Authors
- De Caterina, R., Husted, S., Wallentin, L., De Caterina, R., Husted, S., Wallentin, L., Andreotti, F., Arnesen, H., Bachmann, F., Baigent, C., Huber, K., Jespersen, J., Kristensen, S. D., Lip, G. Y. H., Morais, J., Rasmussen, L. H., Siegbahn, A., Verheugt, F. W. A., & Weitz, J. I.
- Venue
- Journal of the American College of Cardiology
- Publisher
- Elsevier BV
- Published
- 2012-04
- Volume
- 59
- Issue
- 16
- Pages
- 1413-1425
- ISSN
- 0735-1097 (ISSN-L)
- OpenAlex
- W2144939065
- Cited by
- 265
- References
- 34
- FWCI
- 31.84
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.